Umeå universitets logga

umu.sePublikationer
Driftstörningar
Det förekommer återkommande driftstörningar på några av sök-portalerna på grund av hög belastning. Vi arbetar på att lösa problemet, ni kan tillfälligt mötas av ett felmeddelande.
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Characteristics of adult severe uncontrolled asthma patients in primary care and modifications in prescribed inhalation treatments
Astrid Lindgren’s Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin. Medical Affairs, AstraZeneca AB, Stockholm, Sweden.
Department of Respiratory Medicine and Allergology, COPD Center, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Academic Primary Health Care Centre, Stockholm, Sweden; Department of Women’s and Children’s health, Uppsala University, Uppsala, Sweden.
Visa övriga samt affilieringar
2026 (Engelska)Ingår i: Journal of Asthma and Allergy, ISSN 1178-6965, Vol. 19, artikel-id 585933Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Severe asthma outcomes in primary care are poorly documented. This study characterizes adults with severe uncontrolled asthma and evaluates modifications of prescribed inhalation therapy and exacerbations over 12 months.

Methods: Adult primary care asthma patients, with visits recorded in the Swedish National Airway Register from July 2017 to February 2019 (index date), were included. Data were linked to National Prescribed Drug Register. Severe asthma was defined by adherence to high dose inhaled corticosteroids (ICS) ± long-acting beta-agonists (LABA) or ICS+LABA+long-acting muscarinic antagonists. Inhalation therapy was assessed 12 months pre- and post-index. All other variables were collected up to 24 months pre-index and 12 months post-index. Uncontrolled asthma was defined as Asthma Control Test ≤19.

Results: Severe asthma was identified in 2789 patients, of which, 1261 had uncontrolled disease. Severe uncontrolled asthma associated with regular OCS use 24 months pre-index (OR 1.77, 95% CI 1.42–2.20), obesity (1.63, 1.32–2.02), primary school education (1.55, 1.22–1.96) and inversely associated with asthma management education (0.77, 0.66–0.90). Post-index, 5%, 55% and 45% increased, maintained or reduced their inhalation therapy, respectively. Patients increasing inhalation therapy had lower mean FEV1% predicted (67.8 vs. 80.9 and 79.4), more regular OCS uses pre-index (34.8% vs. 17% and 21.9%), and high SABA use (33.3% vs. 27.3% and 21.3%). Post-index asthma exacerbations in severe uncontrolled asthma associated with rhinitis (1.46, 95% CI 1.14–1.88), cardiovascular disease (1.38, 1.06–1.80), high SABA use (1.79, 1.38–2.34), and treatment increase (1.83, 1.08–3.10).

Conclusion: In primary care, severe uncontrolled asthma was among other factors associated with regular OCS use, obesity, lower educational level and absence of asthma management education. Uncontrolled patients already adhering to high dose ICS medication and further increased inhalation therapy were at greater risk of exacerbations, indicating the need for referral to secondary care.

Ort, förlag, år, upplaga, sidor
Dove Medical Press, 2026. Vol. 19, artikel-id 585933
Nyckelord [en]
asthma management, inhalation adjustment, treatment outcome
Nationell ämneskategori
Lungmedicin och allergi
Identifikatorer
URN: urn:nbn:se:umu:diva-251689DOI: 10.2147/JAA.S585933ISI: 001719788800001PubMedID: 41878748Scopus ID: 2-s2.0-105033293510OAI: oai:DiVA.org:umu-251689DiVA, id: diva2:2050607
Forskningsfinansiär
AstraZenecaHjärt-Lungfonden, 2022-0478Hjärt-Lungfonden, 20230537Hjärt-Lungfonden, 20230473Umeå universitetRegion VästerbottenRegion StockholmSvenska Frimurare OrdenKonsul Th C Berghs Stiftelse för vetenskaplig forskningAstma- och AllergiförbundetTillgänglig från: 2026-04-02 Skapad: 2026-04-02 Senast uppdaterad: 2026-04-02Bibliografiskt granskad

Open Access i DiVA

fulltext(3377 kB)423 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 3377 kBChecksumma SHA-512
e463a37a12c2ab500e009f2fe5477c58d474824f94641f04fc698cbcce7ee3d8b806b8374c05148892ef0997cb5b5ab9ef99d98c6ce230457f6c350bb75a34f5
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Packham, SylviaStridsman, Caroline

Sök vidare i DiVA

Av författaren/redaktören
Packham, SylviaStridsman, Caroline
Av organisationen
Institutionen för folkhälsa och klinisk medicin
I samma tidskrift
Journal of Asthma and Allergy
Lungmedicin och allergi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 270 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf